company background image
CTTC logo

Calmare Therapeutics OTCPK:CTTC Stock Report

Last Price

US$0.000001

Market Cap

US$38.0

7D

0%

1Y

n/a

Updated

18 Jul, 2023

Data

Company Financials

Calmare Therapeutics Incorporated

OTCPK:CTTC Stock Report

Market Cap: US$38.0

CTTC Stock Overview

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. More details

CTTC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Calmare Therapeutics Incorporated Competitors

Price History & Performance

Summary of share price highs, lows and changes for Calmare Therapeutics
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$0.025
52 Week LowUS$0.000001
Beta0
1 Month Change-90.00%
3 Month Changen/a
1 Year Changen/a
3 Year Change-100.00%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

CTTCUS Medical EquipmentUS Market
7D0%0.8%0.6%
1Yn/a10.0%23.7%

Return vs Industry: Insufficient data to determine how CTTC performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how CTTC performed against the US Market.

Price Volatility

Is CTTC's price volatile compared to industry and market?
CTTC volatility
CTTC Average Weekly Movementn/a
Medical Equipment Industry Average Movement8.0%
Market Average Movement6.3%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: CTTC's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine CTTC's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1968n/aConrad Mirwww.calmaretherapeutics.com

Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014.

Calmare Therapeutics Incorporated Fundamentals Summary

How do Calmare Therapeutics's earnings and revenue compare to its market cap?
CTTC fundamental statistics
Market capUS$38.00
Earnings (TTM)-US$3.83m
Revenue (TTM)US$1.14m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CTTC income statement (TTM)
RevenueUS$1.14m
Cost of RevenueUS$373.29k
Gross ProfitUS$771.48k
Other ExpensesUS$4.60m
Earnings-US$3.83m

Last Reported Earnings

Dec 31, 2016

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did CTTC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/07/18 02:28
End of Day Share Price 2023/07/06 00:00
Earnings2016/12/31
Annual Earnings2016/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Calmare Therapeutics Incorporated is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ajay TandonSeeThruEquity, LLC
Juan NobleTaglich Brothers, Inc.
Brian MarckxZacks Investment Research Inc.